Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizo-phr Res 2009;110:1-23.
Parnas J. A disappearing heritage: the clinical core of schizo phrenia. Schizophr Bull 2011;37:1121-30.
Raballo A. Self-disorders and the experiential core of schizophrenia spectrum vulnerability. Psychiatr Danub 2012;24(Suppl 3):S303-10.
Sass LA, Parnas J. Schizophrenia, consciousness, and the self. Schizophr Bull 2003;29:427-44.
Rees E, Kirov G, Walters JT, et al. Analysis of exome se quence in 604 trios for recessive genotypes in schizophre nia. Transl Psychiatry 2015;5:e607.
Lee ST, Ryu S, Kim SR, et al. Association study of 27 an notated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharma-col 2012;32:441-8.
International Schizophrenia C, Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizo phrenia and bipolar disorder. Nature 2009;460:748-52.
Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizo phrenia. Nat Genet 2013;45:1150-9.
Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five ma jor psychiatric disorders: a genome-wide analysis. Lancet 2013;381:1371-9.
Schizophrenia Psychiatric Genome-Wide Association Study C. Genome-wide association study identifies five new schiz ophrenia loci. Nat Genet 2011;43:969-76.
Schizophrenia Working Group of the Psychiatric Genom-ics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421-7.
Nica AC, Dermitzakis ET. Expression quantitative trait lo ci: present and future. Philos Trans R Soc Lond B Biol Sci 2013;368:20120362.
Psychiatric GCCC, Cichon S, Craddock N, et al. Genom-ewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009;166:540-56.
Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet 2013;9:e1003348.
Shorter KR, Miller BH. Epigenetic mechanisms in schizo phrenia. Prog Biophys Mol Biol 2015;118:1-7.
Grayson DR, Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neu-ropsychopharmacology 2013;38:138-66.
Guo JU, Su Y, Zhong C, et al. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 2011;10:2662-8.
Xiao Y, Camarillo C, Ping Y, et al. The DNA methylome and transcriptome of different brain regions in schizophrenia and bipolar disorder. PLoS One 2014;9:e95875.
Grayson DR, Jia X, Chen Y, et al. Reelin promoter hyper-methylation in schizophrenia. Proc Natl Acad Sci USA 2005;102:9341-6.
Lott SA, Burghardt PR, Burghardt KJ, et al. The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. Pharmacogenomics J 2013;13:264-71.
Bonsch D, Wunschel M, Lenz B, et al. Methylation matters? Decreased methylation status of genomic DNA in the blood of schizophrenic twins. Psychiatry Res 2012;198:533-7.
Zhang D, Cheng L, Badner JA, et al. Genetic control of in dividual differences in gene-specific methylation in human brain. Am J Hum Genet 2010;86:411-9.
Consortium EP. An integrated encyclopedia of DNA ele ments in the human genome. Nature 2012;489:57-74.
Barry G, Mattick JS. The role of regulatory RNA in cognitive evolution. Trends Cogn Sci 2012;16:497-503.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610.
de Bartolomeis A, Iasevoli F, Tomasetti C, et al. MicroRNAs in schizophrenia: implications for synaptic plasticity and dopamine-glutamate interaction at the postsynaptic density. New avenues for antipsychotic treatment under a theranos-tic perspective. Mol Neurobiol 2014;52:1771-90.
Konopka W, Kiryk A, Novak M, et al. MicroRNA loss enhances learning and memory in mice. J Neurosci 2010;30:14835-42.
Banerjee S, Neveu P, Kosik KS. A coordinated local transla-tional control point at the synapse involving relief from si lencing and MOV10 degradation. Neuron 2009;64:871-84.
Im HI, Kenny PJ. MicroRNAs in neuronal function and dys function. Trends Neurosci 2012;35:325-34.
Arion D, Corradi JP, Tang S, et al. Distinctive transcriptome al terations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. Mol Psychiatry 2015;20:1397-405.
Jaffe AE, Shin J, Collado-Torres L, et al. Developmental regu lation of human cortex transcription and its clinical relevance at single base resolution. Nat Neurosci 2015;18:154-61.
Weinberger DR. Premorbid neuropathology in schizophre nia. Lancet 1988;2:445.
Iasevoli F, Tomasetti C, Buonaguro EF, et al. The glutamater-gic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol 2014;12:219-38.
Chung W, Choi SY, Lee E, et al. Social deficits in IRSp53 mu tant mice improved by NMDAR and mGluR5 suppression. Nat Neurosci 2015;18:435-43.
Gauthier J, Champagne N, Lafreniere RG, et al. De novo mutations in the gene encoding the synaptic scaffolding pro tein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci USA 2010;107:7863-8.
Errico F, D'Argenio V, Sforazzini F, et al. A role for D-aspar-tate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Transl Psy chiatry 2015;5:e512.
de Bartolomeis A, Errico F, Aceto G, et al. D-aspartate dysregulation in Ddo(-/-) mice modulates phencyclidine-induced gene expression changes of postsynaptic density molecules in cortex and striatum. Prog Neuropsychophar-macol Biol Psychiatry 2015;62:35-43.
Dawson N, Kurihara M, Thomson DM, et al. Altered func tional brain network connectivity and glutamate system function in transgenic mice expressing truncated Disrupted-in-Schizophrenia 1. Transl Psychiatry 2015;5:e569.
Iasevoli F, Ambesi-Impiombato A, Fiore G, et al. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first-and second-generation antipsychot-ics: effect of short-term drug discontinuation and compari son with Homer1a-interacting genes. J Psychopharmacol 2011;25:875-87.
Iasevoli F, Buonaguro EF, Sarappa C, et al. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Prog Neuropsy-chopharmacol Biol Psychiatry 2014;54:299-314.
de Bartolomeis A, Marmo F, Buonaguro EF, et al. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density tran scripts compared to haloperidol. Eur Neuropsychopharma-col 2013;23:1516-29.
Tomasetti C, Dell'Aversano C, Iasevoli F, et al. The acute and chronic effects of combined antipsychotic-mood sta bilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:184-97.
Iasevoli F, Polese D, Ambesi-Impiombato A, et al. Keta-mine-related expression of glutamatergic postsynaptic den sity genes: possible implications in psychosis. Neurosci Lett 2007;416:1-5.
Wheeler AL, Creed MC, Voineskos AN, et al. Changes in brain functional connectivity after chronic haloperidol in rats: a net work analysis. Int J Neuropsychopharmacol 2014;17:1129-38.
Zipursky RB, Marsh L, Lim KO, et al. Volumetric MRI as sessment of temporal lobe structures in schizophrenia. Biol Psychiatry 1994;35:501-16.
Shepherd AM, Laurens KR, Matheson SL, et al. System atic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev 2012;36:1342-56.
Pergola G, Selvaggi P, Trizio S, et al. The role of the thalamus in schizophrenia from a neuroimaging perspective. Neuro-sci Biobehav Rev 2015;54:57-75.
Deco G and Kringelbach ML. Great expectations: using whole-brain computational connectomics for understand ing neuropsychiatric disorders. Neuron 2014;84:892-905.
Ellison-Wright I and Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 2009;108:3-10.
Callicott JH, Bertolino A, Mattay VS, et al. Physiological dys function of the dorsolateral prefrontal cortex in schizophre nia revisited. Cereb Cortex 2000;10:1078-92.
Karlsgodt KH, Sanz J, van Erp TG, et al. Re-evaluating dorso-lateral prefrontal cortex activation during working memory in schizophrenia. Schizophr Res 2009;108:143-50.
Fusar-Poli P. Voxel-wise meta-analysis of fMRI studies in pa tients at clinical high risk for psychosis. J Psychiatry Neurosci 2012;37:106-12.
Wolf DH, Satterthwaite TD, Calkins ME, et al. Functional neuroimaging abnormalities in youth with psychosis spec trum symptoms. JAMA Psychiatry 2015;72:456-65.
Blasi G, Selvaggi P, Fazio L, et al. Variation in dopamine D2 and serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics. Neuropsychopharmacology 2015;40:1600-8.
Di Giorgio A, Caforio G, Blasi G, et al. Catechol-O-methyl-transferase Val(158)Met association with parahippocampal physiology during memory encoding in schizophrenia. Psy-chol Med 2011;41:1721-31.
Blasi G, De Virgilio C, Papazacharias A, et al. Converging evi dence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olan-zapine treatment. JAMA Psychiatry 2013;70:921-30.
Sporns O. Contributions and challenges for network models in cognitive neuroscience. Nat Neurosci 2014;17:652-60.
Anticevic A, Hu S, Zhang S, et al. Global resting-state func tional magnetic resonance imaging analysis identifies frontal cortex, striatal, and cerebellar dysconnectivity in obsessive-compulsive disorder. Biol Psychiatry 2014;75:595-605.
Minzenberg MJ, Laird AR, Thelen S, et al. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry 2009;66:811-22.
Fornito A, Zalesky A, Breakspear M. The connectomics of brain disorders. Nat Rev Neurosci 2015;16:159-72.
Khan ZU, Martin-Montanez E, Muly EC. Schizophrenia: causes and treatments. Curr Pharm Des 2013;19:6451-61.
Cuesta MJ, Peralta V. Integrating psychopathological di mensions in functional psychoses: a hierarchical approach. Schizophr Res 2001;52:215-29.
Huber G, Gross G. The concept of basic symptoms in schiz ophrenic and schizoaffective psychoses. Recenti Prog Med 1989;80:646-52.
Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizo-phr Bull 2009;35:5-8.
Raballo A, Parnas J. Examination of anomalous self-experi ence: initial study of the structure of self-disorders in schizo phrenia spectrum. J Nerv Ment Dis 2012;200:577-83.
Henriksen MG, Parnas J. Self-disorders and schizophrenia: a phenomenological reappraisal of poor insight and noncom-pliance. Schizophr Bull 2014;40:542-7.
Schultze-Lutter F, Ruhrmann S, Picker H, et al. Basic symp toms in early psychotic and depressive disorders. Br J Psy chiatry Suppl 2007;51:s31-7.
Schultze-Lutter F, Ruhrmann S, Fusar-Poli P, et al. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des 2012;18:351-7.
Klosterkotter J, Hellmich M, Steinmeyer EM, et al. Diagnos ing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001;58:158-64.
Parnas J, Handest P. Phenomenology of anomalous self-experience in early schizophrenia. Compr Psychiatry 2003;44:121-34.
Klosterkotter J, Ebel H, Schultze-Lutter F, et al. Diagnostic validity of basic symptoms. Eur Arch Psychiatry Clin Neuro-sci 1996;246:147-54.
Parnas J, Handest P, Saebye D, et al. Anomalies of subjective experience in schizophrenia and psychotic bipolar illness. Acta Psychiatr Scand 2003;108:126-33.
Haug E, Lien L, Raballo A, et al. Selective aggregation of self-disorders in first-treatment DSM-IV schizophrenia spectrum disorders. J Nerv Ment Dis 2012;200:632-6.
Nordgaard J, Parnas J. Self-disorders and the schizophrenia spectrum: a study of 100 first hospital admissions. Schizo-phr Bull 2014;40:1300-7.
Parnas J. The core Gestalt of schizophrenia. World Psychia try 2012;11:67-9.
Nelson B, Thompson A, Yung AR. Basic self-disturbance predicts psychosis onset in the ultra high risk for psychosis "prodromal" population. Schizophr Bull 2012;38:1277-87.
Raballo A, Parnas J. The silent side of the spectrum: schizotypy and the schizotaxic self. Schizophr Bull 2011;37:1017-26.
Raballo A, Saebye D, Parnas J. Looking at the schizophrenia spectrum through the prism of self-disorders: an empirical study. Schizophr Bull 2011;37:344-51.
Maggini C, Raballo A. Subjective experience of personality dimensions in 1st degree relatives of schizophrenics. Acta Biomed 2003;74:131-6.
Maggini C, Raballo A. Subjective experience of schizotropic vulnerability in siblings of schizophrenics. Psychopathology 2004;37:23-8.
Maggini C, Raballo A, Pelizza L, et al. Subjective experience of language impairment and psychopathology in schizo phrenia. Psychopathology 2003;36:17-22.
Raballo A. The schizotaxic self: phenotyping the silent pre disposition to schizophrenia spectrum disorders. Med Hy potheses 2009;73:121-2.
